Credit Suisse Ag Mei Pharma, Inc. Transaction History

Credit Suisse Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$2.6 - $3.65 $33,191 - $46,595	-12,766 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$2.73 - $4.5 $49,060 - $80,869	-17,971 Reduced 58.47%	12,766 $44,000
Q4 2020 Feb 12, 2021	BUY	$2.6 - $3.32 $79,916 - $102,046	30,737 New	30,737 $81,000
Q3 2020 Nov 13, 2020	SELL	$2.46 - $4.27 $27,399 - $47,559	-11,138 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$1.45 - $4.3 $16,150 - $47,893	11,138 New	11,138 $46,000
Q4 2019 Feb 12, 2020	SELL	$1.65 - $2.48 $26,203 - $39,384	-15,881 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$1.48 - $2.52 $7,479 - $12,736	5,054 Added 46.68%	15,881 $26,000
Q2 2019 Aug 14, 2019	BUY	$2.45 - $3.32 $26,526 - $35,945	10,827 New	10,827 $27,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $366M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.